Influenza Vaccine Market Thumbnail Image

2021

Influenza Vaccine Market

Influenza Vaccine Market Size, Share, Competitive Landscape and Trend Analysis Report by Vaccine Type, Technology, Age Group and Route of Administration : Global Opportunity Analysis and Industry Forecast, 2021-2030

LS : Pharmaceuticals

Select an option
Author's: Vishal Bhardwaj| Ajinkya Alhat| Shubham Choudante | Roshan Deshmukh
Publish Date:

Get Sample to Email

The global influenza vaccine market size was valued at $5024.60 million in 2020, and is projected to reach $10,127.0 million by 2030, registering a CAGR of 7.20% from 2021 to 2030. The viral infection which occurs due to flu in the respiratory system is called influenza. Influenza virus travels through respiratory droplets and it is contagious. It can also spread from one person to another while talking or due to physical contact. The influenza virus circulates continuously, causing regional epidemics and outbreaks which leads to thousands of deaths. Changing character of the virus is compelling an annual change in the vaccine strain to match the influenza virus strain. Healthcare organizations all over the world like Centers for Disease Control and Prevention (CDC) have suggested vaccines like baloxavir marboxil (Xofluza) for the treatment of influenza have recommended certain influenza vaccines such as baloxavir marboxil (Xofluza) to treat the symptoms in patients.

The vaccines used for influenza are made up of three different influenza viruses like influenza type A with H3N2 virus strain, influenza type A with H1N1 virus strain, and influenza type B virus strain. Increase in prevalence of influenza epidemics and seasonal outbreaks is likely to expand the product sales during the projected period.

Influenza-Vaccine-market

Increase in government support and surveillance regarding vaccination against influenza on the national and global levels to monitor the supply, distribution, and administration of flu vaccines is one of the crucial factors driving the market growth. Moreover, increase in investment by leading market players across the globe and rise in government funding have facilitated the launch of therapeutically effective vaccines drive the influenza vaccine market growth.

The immunization camps and programs conducted by various healthcare organizations have been affected due to the coronavirus pandemic. Having said that, the rates of the vaccination for flu has reached its peak in the pandemic due to a push by various healthcare operatives and government who are providing free vaccination to the citizens. Awareness has also raised amongst the populations due to the fear of flu and COVID-19.

Influenza Vaccine Market
By Vaccine Type
Your browser does not support the canvas element.

Quadrivalent segment held a dominant position in 2020 and would continue to maintain the lead over the forecast period.

Novel vaccine development is a huge process that generally takes about 10-15 years to develop and establish its safety and efficacy. Regulatory requirements for clinical trials vary in countries, which may delay the development of vaccines which limit the growth of the market.

Many companies like Sanofi, Emergent BioSolutions Inc., and F. Hoffmann-La Roche Ltd, are also helping in the distribution. On the other hand, many countries are facing undersupplies and delay in the approvals of vaccines and availability of vaccines due to the strict regulations during the clinical trials extending the timelines of vaccines delivery.

Influenza Vaccine Market
By Technology
Your browser does not support the canvas element.

Egg-Based segment is projected as one of the most lucrative segment.

Global Influenza Vaccine Market Segmentation

The influenza vaccine market is segmented into vaccine type, technology, age group, route of administration and region. By vaccine type, it is divided into quadrivalent and trivalent. By technology, it is classified into egg-based and cell-based. By age group, it is divided into pediatric and adult. By route of administration, it is categorized into injection and nasal spray. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Segment review

By vaccine type, it is divided into quadrivalent and trivalent. The quadrivalent type segment was the major revenue contributor in 2020, owing to its ability to immunize four influenza virus strains (two A subtypes and two B subtypes — H1N1 and H3N2 and Victoria and Yamagata, respectively). By technology, it is classified into egg-based and cell-based. 

Influenza Vaccine Market
By Age Group
Your browser does not support the canvas element.

Adult segment is projected as one of the most lucrative segment.

The egg-based technology segment dominates the technology segment as it is most commonly used in production of both inactivated and live-attenuated vaccines. By age group, it is bifurcated into pediatric and adult. The adult age group segment was the highest contributor in the influenza vaccine market in 2020 and is expected to remain dominant during the forecast period, owing to higher risks of developing serious complications from influenza due to weaker immune response.  

North America accounted for the largest influenza vaccine market share in 2020 and is expected to retain its dominance throughout the forecast period. This is attributed to the increased prevalence of influenza in the region, increase in government focus on immunization programs, emergence of new vaccines, and growth in technological advancements for vaccine administration. However, Middle East and Africa is expected to emerge as a lucrative area with maximum growth potential, due to the increase in awareness program, improvement in healthcare facilities, available disposable income, and rapid development of economic conditions.

Influenza Vaccine Market
By Route Of Administration
Your browser does not support the canvas element.

Injection segment is projected as one of the most lucrative segment.

Some of the key players operating in the influenza vaccine market are AstraZeneca plc., Biodiem, CSL Limited, Emergent BioSolutions, F. Hoffmann-La Roche Ltd., Gamma Vaccines Pty Ltd., GlaxoSmithKline plc, Merck & Co. Inc. (Merck Sharp & Dohme Corp.), Novartis AG, Pfizer, Inc., Sanofi Pasteur SA, and Sinovac Biotech Ltd. 

Influenza Vaccine Market
By Region
2030
North America 
Europe
Asia-Pacific
LAMEA

North America was holding a dominant position in 2020 and would continue to maintain the lead over the analysis period.

Key Benefits For Stakeholders

  • This report provides an extensive analysis of the current and emerging market trends and dynamics in the global influenza vaccine market to identify the prevailing opportunities.
  • This study presents the competitive landscape of the global influenza vaccine market to predict the competitive environment across geographies.
  • Comprehensive analysis of factors that drive and restrict the influenza vaccine market growth is provided.
  • Region- & country-wise analysis is provided to understand the influenza vaccine market trends and dynamics

Key Market Segments

By Vaccine Type

  • Quadrivalent
  • Trivalent

By Type

  • Seasonal
  • Pandemic

By Technology

  • Egg-based
  • Cell-based

By Age Group

  • Pediatric
  • Adult 

By Route Of Administration

  • Injection
  • Nasal Spray

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Australia
    • Japan
    • India
    • China
    • South Korea
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Rest of Latin America
    • Middle East and Africa
    • Saudi Arabia
    • South Africa
    • Rest of Middle East and Africa

Key Market Players 

  • Astrazeneca Plc (Astrazeneca)
  • Biodiem
  • Csl Limited (Seqirus GmbH)
  • Emergent Biosolutions
  • F. Hoffmann-La Roche Ltd.
  • Gamma Vaccines Pty Ltd.
  • Glaxosmithkline Plc
  • Merck & Co., Inc. (Merck Sharp & Dohme Corp.)
  • Novartis Ag
  • Pfizer, Inc.
  • Sanofi
  • Sinovac Biotech Ltd.

Influenza Vaccine Market Report Highlights

Aspects Details
icon_5
By VACCINE TYPE
  • VACCINE TYPE
  • Trivalent
icon_6
By TECHNOLOGY
  • Egg-based
  • Egg-based
icon_7
By AGE GROUP
  • Pediatric
  • Adult
icon_8
By ROUTE OF ADMINISTRATION
  • Injection
  • Nasal spray
icon_9
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Russia, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Thailand, Malaysia, Indonesia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, UAE, Argentina, Rest of LAMEA)
icon_10
Key Market Players

PFIZER, INC., GAMMA VACCINES PTY LTD., SANOFI, HOFFMANN-LA ROCHE LTD., GLAXOSMITHKLINE PLC, EMERGENT BIOSOLUTIONS INC., ASTRAZENECA PLC (ASTRAZENECA), BIODIEM LTD, MERCK & CO., INC. (MERCK SHARP & DOHME CORP.), CSL LIMITED (SEQIRUS GMBH)

Analyst Review

According to analyst perspective, the influenza vaccine industry holds the maximum potential, owing to the increase in R&D activities related to influenza vaccines, growth in immunization programs, and rise in the incidences of influenza globally which, in turn, are responsible to drive the market growth. Furthermore, significant technological advancements in the manufacturing technology of vaccines to improve efficacy and potency of vaccines along with increased investments by manufacturers to upgrade traditional vaccination production and delivery methods contribute to increased profit margins and enhanced operational efficiencies in the production of influenza vaccines, especially in the U.S. Novel vaccine development generally takes about 10-15 years to develop and establish its safety and efficacy which is a huge process and regulatory requirements for clinical trials vary in countries may delay in development of vaccines which is projected to limit the growth of the market.

Author Name(s) : Vishal Bhardwaj| Ajinkya Alhat| Shubham Choudante | Roshan Deshmukh
Frequently Asked Questions?

The total market value of Influenza Vaccine Market is $5024.60 million in 2020

The forcast period for Influenza Vaccine Market is 2021 to 2031

The market value of Influenza Vaccine Market in 2030 is $10,127.00 million.

The base year is 2020 in Influenza Vaccine Market.

Astrazeneca, Biodem Ltd., CSL Ltd., Emergent Biosolutions Ltd., Roche held a high market postion owing to the strong geographical foothold in different regions.

Quadrivalent segment dominates the global market, this is attributed to the number of pharmaceutical companies producing this vaccines.

The major factor for the growth of Influenza Vaccine Market are high prevalence of influenza, increase in government focus on immunization programs, emerging vaccines and technological progress in vaccine administration.

Owing to rise in the number of vaccines available in the market along with government initiatives to improve the immunization programs. Furthermore, government initiatives and technological advancements toward flu is expected to propel the demand for Influenza Vaccine Market in the region.

Influenza commonly known as flu is a contagious respiratory infection or illness caused by influenza viruses. The influenza vaccine protects a person from getting the flu.

Flu vaccines are designed to protect against the influenza viruses that are predicted to be the most common during the upcoming season.

Loading Table Of Content...

Individual sections of the reports are available for purchase.
Would you like to see a breakdown of prices by section?

Influenza Vaccine Market

Global Opportunity Analysis and Industry Forecast, 2021-2030